Boston Scientific - BSX Stock Forecast, Price & News

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Canaccord Genuity Group upped their price objective on shares of Boston Scientific from $43.00 to $45.00 in a research report on Thursday, July 28th. Citigroup decreased their price objective on shares of Boston Scientific from $52.00 to $47.00 and set a "buy" rating on the stock in a research report on Tuesday, May 17th. Wolfe Research assumed coverage on shares of Boston Scientific in a research report on Tuesday, July 5th. They set an "outperform" rating and a $43.00 price target on the stock. BTIG Research increased their price target on shares of Boston Scientific from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Thursday, July 28th. Finally, Morgan Stanley reduced their price target on shares of Boston Scientific from $51.00 to $46.00 and set an "overweight" rating on the stock in a research report on Friday, July 15th. Two analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $46.55.

Boston Scientific Stock Performance

NYSE:BSX opened at $42.63 on Friday. The business has a 50 day moving average price of $38.69 and a 200-day moving average price of $41.22. Boston Scientific has a fifty-two week low of $34.98 and a fifty-two week high of $47.49. The firm has a market cap of $60.94 billion, a PE ratio of 73.50, a price-to-earnings-growth ratio of 2.29 and a beta of 0.85. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.86 and a current ratio of 1.31.

Boston Scientific (NYSE:BSX - Get Rating) last announced its quarterly earnings results on Wednesday, July 27th. The medical equipment provider reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.42 by $0.02. Boston Scientific had a return on equity of 14.58% and a net margin of 7.16%. The company had revenue of $3.24 billion during the quarter, compared to analyst estimates of $3.22 billion. During the same quarter last year, the firm posted $0.40 earnings per share. The firm's revenue was up 5.4% on a year-over-year basis. Equities research analysts predict that Boston Scientific will post 1.76 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Eric Francis Yves Thepaut sold 20,676 shares of the firm's stock in a transaction on Monday, August 1st. The stock was sold at an average price of $40.99, for a total value of $847,509.24. Following the completion of the sale, the executive vice president now owns 72,486 shares of the company's stock, valued at $2,971,201.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Wendy Carruthers sold 7,500 shares of the firm's stock in a transaction on Monday, August 15th. The stock was sold at an average price of $42.03, for a total transaction of $315,225.00. Following the completion of the transaction, the executive vice president now directly owns 117,413 shares in the company, valued at $4,934,868.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Eric Francis Yves Thepaut sold 20,676 shares of the firm's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $40.99, for a total value of $847,509.24. Following the transaction, the executive vice president now owns 72,486 shares of the company's stock, valued at $2,971,201.14. The disclosure for this sale can be found here. Insiders sold 59,264 shares of company stock valued at $2,401,673 over the last quarter. 0.71% of the stock is owned by company insiders.